Saturday 17 October 2026
Export BTAIQ’s income statement to Excel — free account
BioXcel Therapeutics, Inc.
BTAIQ Healthcare Drug Manufacturers Specialty & Generic
BioXcel Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $642,000.00, down 71.7% from fiscal 2024. In the quarter to June 2026, revenue grew 51.7%, EPS grew 80.0%, free cash flow grew 51.5% and total debt fell 3.90%, each against the same quarter a year earlier.
0.03
0.00
0.00%
Follow BTAIQ
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
48.33 | 30.42 | 46.45 | 57.58 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(1.93) | (1.37) | (2.67) | (7.01) | |
P/B ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Tangible BV |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Sales |
143.81 | 156.34 | 168.67 | 284.68 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(1.86) | (1.74) | (2.00) | (4.15) | |
EV/FCF |
(1.86) | (1.74) | (2.00) | (4.15) | |
Quick Ratio |
0.99 | 0.54 | 0.32 | 0.10 | |
Current Ratio |
1.17 | 0.83 | 0.62 | 0.21 | |
Net Debt/EBITDA |
(5.07) | (7.92) | (8.18) | (8.91) | |
Debt/Assets |
243.63% | 244.00% | 294.75% | 362.69% | |
Debt/Equity |
(1.23) | (1.15) | (0.95) | (0.90) | |
Asset Turnover |
0.02 | 0.02 | 0.02 | 0.03 | |
Operating CF/Net income |
0.61 | 1.13 | 0.93 | 0.41 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.00 | |
Interest Coverage |
(3.25) | (2.34) | (2.44) | (2.39) | |
Research and Development Expense of Revenue |
8,918.37% | 2,617.58% | 1,434.47% | 1,738.46% | |
Selling, General and Administrative Expense of Revenue |
5,490.82% | 1,486.33% | 3,490.78% | 3,950.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
592.86% | 175.78% | 211.17% | 196.70% | |
Graham Net Nets |
(2.46) | (4.90) | (3.35) | (2.70) | |
Graham Number |
36.97 | 34.36 | 24.07 | 18.03 | |
Earnings Yield |
(378.91%) | (419.38%) | (429.10%) | (268.79%) | |
Free Cash Flow Yield |
(160.24%) | (295.07%) | (181.73%) | (119.20%) | |
Revenue per Share |
0.01 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(1.32) | (1.16) | (0.50) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(1.32) | (1.16) | (0.50) | (0.20) | |
Cash per Share |
2.63 | 2.36 | 0.73 | 0.46 | |
Shareholders Equity per Share |
(6.26) | (7.82) | (4.48) | (3.81) | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
(6.26) | (7.82) | (4.48) | (3.81) | |
Free Cash Flow |
(18.79) | (14.21) | (11.81) | (6.10) | |
Working Capital |
6.60 | (9.24) | (21.09) | (108.45) | |
Net Current Asset Value |
(89.31) | (95.69) | (105.66) | (115.56) | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
— | 0.52 | 0.11 | 0.11 | |
Average Payables |
15.58 | 15.35 | 15.85 | 17.74 | |
Average Inventory |
0.99 | 0.70 | 0.57 | 0.49 | |
Average Assets |
46.84 | 41.63 | 36.30 | 27.29 | |
Average Common Equity |
(87.28) | (94.28) | (97.86) | (111.56) |
Columns are period end dates